스페로 테라퓨틱스(SPRO) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

Q: What kind of company is 스페로 테라퓨틱스(SPRO)?

스페로 테라퓨틱스(SPRO) belongs to the Healthcare sector and operates in the Biotechnology industry.

Q: What is the market cap of SPRO?

The market cap of SPRO is approximately $68M, ranking 4,772 within its sector.

Q: What is the P/E ratio of SPRO?

SPRO has a P/E ratio of approximately 4.8x, which can be used to assess its valuation relative to the Healthcare sector average.

Q: What is the 52-week high and low for SPRO?

SPRO has recorded a 52-week high of $3.08 and a low of $1.08.

SPRO

Spero Therapeutics Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$1.18

-0.01 ▼ -0.84%

🌙 7월 28일 4:05 AM ET (한국 7/28 17:05)

$1.21

+0.03 ▲ +2.54%

스페로 테라퓨틱스(SPRO) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$68M

스몰캡

P/E

4.8

저평가 구간

배당수익률

없음

52주 위치

저점 +9% · 고점 -62%

애널리스트

보유

B-

Fundamental health

vs. Biotechnology

수익성

Top 1%

성장

Top 50%

밸류에이션

Top 86%

재무 안정

Top 34%

💰 Is this stock pricier than usual right now?

Compared to this company's own recent 2년 (not other companies).

Very cheap

Cheap

Typical

Pricey

Very pricey

Simply put — what you pay today to own $1 of this company's yearly earnings is 5원. Over the past 2년, it usually traded around 8원. Roughly in line with its own history.

Pricy doesn't mean bad — it means expectations are already baked in.· based on 1.6 profitable years

Index ⓘ	-	P/E ⓘ	4.84	EPS (ttm) ⓘ	0.24	Insider Own ⓘ	26.06%	Shs Outstand ⓘ	57.9M	Perf Week ⓘ	-18.06%
Market Cap ⓘ	0.07B	Forward P/E ⓘ	1.76	EPS next Y ⓘ	331.03%	Insider Trans ⓘ	-1.29%	Shs Float ⓘ	42.8M	Perf Month ⓘ	-41.58%
Enterprise Value ⓘ	0.01B	PEG ⓘ	-	EPS next Q ⓘ	-	Inst Own ⓘ	14.56%	Short Float ⓘ	4.94%	Perf Quarter ⓘ	-56.93%
Income ⓘ	0.02B	P/S ⓘ	1.25	EPS this Y ⓘ	-293.33%	Inst Trans ⓘ	-1.49%	Short Ratio ⓘ	1.37	Perf Half Y ⓘ	-51.64%
Sales ⓘ	0.05B	P/B ⓘ	1.29	EPS next 5Y ⓘ	-	ROA ⓘ	22.28%	Short Interest ⓘ	2.11M	Perf YTD ⓘ	-49.36%
Book/sh ⓘ	0.91	P/C ⓘ	1.22	EPS past 3/5Y ⓘ	-	ROE ⓘ	35.12%	52W High ⓘ	-61.69% ($3.08)	Perf Year ⓘ	-49.36%
Cash/sh ⓘ	0.97	P/FCF ⓘ	9.44	Sales past 3/5Y ⓘ	7.06% 197%	ROIC ⓘ	28.51%	52W Low ⓘ	9.26% ($1.08)	Perf 3Y ⓘ	-15.11%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	1.89	EPS Y/Y TTM ⓘ	121.5%	Gross Margin ⓘ	-	Volatility(W/M) ⓘ	11.9% 8.92%	Perf 5Y ⓘ	-91.37%
Dividend TTM ⓘ	-	EV/Sales ⓘ	0.27	Sales Y/Y TTM ⓘ	93.5%	Oper. Margin ⓘ	14.16%	ATR (14) ⓘ	0.16	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	10.5	EPS Q/Q ⓘ	49.76%	Profit Margin ⓘ	27.82%	RSI (14) ⓘ	20.72	Recom ⓘ	3
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	10.5	Sales Q/Q ⓘ	-94.95%	SMA20 ⓘ	-34.41% ($1.8)	Beta ⓘ	1.58	Target Price ⓘ	$4
Payout ⓘ	-	Debt/Eq ⓘ	0.05	Earnings ⓘ	2026/5/13	SMA50 ⓘ	-48.59% ($2.3)	Rel Volume ⓘ	0.87	Prev Close ⓘ	$1.19
Employees ⓘ	25	LT Debt/Eq ⓘ	0.01	EPS/Sales Surpr. ⓘ	-	SMA200 ⓘ	-50.5% ($2.38)	Avg Volume(3M) ⓘ	1.55M	Price ⓘ	$1.18
IPO ⓘ	2017/11/2	Option/Short ⓘ	Yes/Yes			Trades ⓘ	2504	Volume ⓘ	1,344,620	Change ⓘ	-0.84%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $0M (YoY -100%) · 순이익 $-7M (YoY +48%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Spero Therapeutics Inc (SPRO) Investment Analysis

What kind of company is Spero Therapeutics Inc?

스페로 테라퓨틱스(SPRO) 초고성장주

Healthcare · Biotechnology

Small-Cap — Low Volume, High Volatility

Spero Therapeutics is a US-based, clinical-stage biopharmaceutical company developing novel antibiotics to combat multi-drug-resistant infectious diseases. Its portfolio includes oral carbapenem-class antibiotics and other candidate compounds targeting gram-negative and non-tuberculous mycobacterial (NTM) infections. Through collaborations with major pharmaceutical companies, the company is expanding its pipeline in the antibacterial field, where there is significant unmet medical need.

Learn more about Spero Therapeutics Inc →

Market Cap

$0.1B

Approx. KRW 0.1 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank4772

Employees25people

IPO2017/11/02

Current Price$1.18 ≈ 1,617원

NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 13일 (수) · 장 마감 후

🔔 Earnings release 2026년 3월 26일 (목) · 장 마감 후

Is it profitable?

Solid company — profitability & finances both healthy

Strong earnings and excellent financial health

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

14.2%

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology 초소형주 Median -778.0% · Top tier

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

27.8%

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology 초소형주 Median -911.1% · Top tier

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

ROE

Annual return earned on shareholders' equity (15%+ is strong)

35.1%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 초소형주 Median -98.0% · Top tier

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

22.3%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 초소형주 Median -59.3% · Top tier

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

28.5%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 초소형주 Median -77.3% · Top tier

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.05

✓ Healthy debt

My positionMid-range

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

10.50

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

10.50

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook

Price targets, growth, and valuation are favorable

애널리스트 목표가

$4.00

현재가 대비 +239.0%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

1.76배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

내년 EPS 예상 성장률

+331.0%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth

Mid-range within the industry

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

-293.3%

매우 부진

My positionBottom 5%

Low range Average High range

초고성장주 초소형주 Median 50.1% · Bottom tier

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+331.0%

우수

My positionTop 5%

Low range Average High range

초고성장주 초소형주 Median 35.0% · Top tier

📊 How much has it grown? (actual results)

Past 5-Year Revenue

How much revenue grew over the past 5 years

+197.0%

우수

My positionTop 5%

Low range Average High range

초고성장주 초소형주 Median 47.0% · Top tier

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

-95.0%

매우 부진

My positionBottom 5%

Low range Average High range

초고성장주 초소형주 Median 3.6% · Bottom tier

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -160%p below the market

SPRO -91.4% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-159.7%p

Significantly behind the market

vs Health Care (XLV)

-115.9%p

Significantly behind the sector average

1-year basis

vs S&P 500

-65.4%p

Significantly behind the market

vs Health Care (XLV)

-69.1%p

Significantly behind the sector average

Rank among peers

5-year return Upper-Mid (36%) Based on 245 peers

1-year return Lower-Mid (lower 49%) Based on 315 peers

Current position within 52-week range

Low (-9.3%p) High (-61.7%p)

Current price is 9.3% above the 52-week low and 61.7% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-61.1%

Annualized volatility

77.5%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-27

Downtrend zone

Current price $1.18 below the midline ($1.80). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴

Current diagnosis · 2026-07-27

Bearish momentum holding

MACD -0.321 < Signal -0.263 in negative zone + Hist negative (-0.058). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔵

Current diagnosis · 2026-07-27

Oversold zone — rebound potential

RSI 20.9 (30 or below). Selling pressure is excessive; a short-term rebound may be worth considering. Stoch %K is also 7.9.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Earnings·Vs. Assets·Vs. Sales·Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Cheap

🏢 Vs. Assets Cheap

🧾 Vs. Sales Cheap

💧 Vs. Cash Flow Cheap

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

4.84x

✓ Very cheap

My positionTop 25%

Low range Average High range

Biotechnology median 15.34x · Top 21% — relatively cheap within the industry

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

1.76x

✓ Very cheap

My positionTop 5%

Low range Average High range

Biotechnology median 20.98x · Top 1% — relatively cheap within the industry

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

1.29x

✓ Cheap

My positionMid-range

Low range Average High range

Biotechnology 초소형주 median 1.35x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

1.25x

✓ Very cheap

My positionTop 5%

Low range Average High range

Biotechnology 초소형주 median 11.24x · Top 1% — relatively cheap within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

1.89x

✓ Very cheap

My positionTop 5%

Low range Average High range

Biotechnology median 22.58x · Top 1% — relatively cheap within the industry

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

9.44x

✓ Very cheap

My positionTop 25%

Low range Average High range

Biotechnology median 18.43x · Top 13% — relatively cheap within the industry

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$4.00 vs. current price +239.0%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology

Who owns it?

Ownership backdrop is unfavorable

Insider modest net selling -1.3% · Institutional net selling -1.5% · Short interest light 4.9% · Short interest up +3.5pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-1.3%

Insiders net selling

🏦 Institutions (funds & investors)

-1.5%

Institutions net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 14.6%

Retail-led

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 26.1%

Founder/management large holders (strong skin-in-the-game)

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 59.4%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

4.9%

Low — limited short-side pressure

Healthcare 초소형주 Median 3.9%

Past 90 days 📈 +3.5%p increase

Short interest days to cover

1.4 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 57.9M주

Float (tradable shares) 42.8M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding SPRO

ETFs with the highest weightings · 6 total shown

QQQS

Invesco NASDAQ Future Gen 200 ETF

0.42%

$21M

DFAC

Dimensional U.S. Core Equity 2 ETF

0.00%

$47.5B

DFAS

Dimensional U.S. Small Cap ETF

0.00%

$15.2B

PRFZ

Invesco RAFI US 1500 Small-Mid ETF

0.00%

$2.8B

VTI

Vanguard Total Stock Market ETF

0.00%

$657.4B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
SPRO This Stock	$68.3M	4.8 ▲	1.3 ▲	35.12% ▲	-	-0.8%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 스페로 테라퓨틱스(SPRO)?

스페로 테라퓨틱스(SPRO) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of SPRO?

The market cap of SPRO is approximately $68M, ranking 4,772 within its sector.

What is the P/E ratio of SPRO?

SPRO has a P/E ratio of approximately 4.8x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for SPRO?

SPRO has recorded a 52-week high of $3.08 and a low of $1.08.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.